Cambridge Oncometrix ^Companies

Cambridge Oncometrix aims to save lives by enabling the early detection of prostate cancer - a condition that affects 1 in 7 men on the planet. The company develops a non-invasive risk stratification test for prostate cancer. The laboratory test will be capable of accurately selecting men for mpMRI-guided biopsy.